USFDA vigilance on Chinese drug companies may benefit Indian counterparts – The Economic Times

Indian drug makers see a significant business opportunity in the American regulator’s decision to step up vigilance on Chinese companies that could lead to a dip in China’s exports.

US Food and Drug Administration has decided to increase its inspection staff more than threefold in China to 26 from eight and the number of drug inspectors to 11 from just one at present.